Prostatic Neoplasms

• EMA withdrawal · 2022-05-20
  EMA Withdrawn: Docetaxel Zentiva (previously Docetaxel Winthrop) (docetaxel) — Zentiva k.s.

  The EMA has withdrawn Docetaxel Zentiva (docetaxel) from the market. The therapeutic areas formerly associated include head and neck neoplas…

• EMA withdrawal · 2021-12-14
  EMA Withdrawn: Docetaxel Teva (docetaxel) — Teva B.V.

  The EMA has withdrawn Docetaxel Teva, an injectable chemotherapy containing docetaxel, from the European market.

• EMA withdrawal · 2019-10-15
  EMA Withdrawn: Taxespira (previously Docetaxel Hospira UK Limited ) (docetaxel trihydrate) — Hospira UK Limited

  The EMA withdrew Taxespira (docetaxel trihydrate) from the market for multiple cancer indications including stomach, prostate, breast, head …

• EMA withdrawal · 2019-07-24
  EMA Refused: Cabazitaxel Teva (cabazitaxel) — Teva B.V.

  The EMA refused the cabazitaxel product Teva B.V. for therapeutic use in prostatic neoplasms.

• EMA withdrawal · 2016-09-29
  EMA Application withdrawn: Docetaxel SUN — Sun Pharmaceutical Industries Europe B.V.

  The EMA withdrew the application for Docetaxel SUN by Sun Pharmaceutical Industries Europe B.V. for multiple cancer indications.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA withdrawal · 2015-03-12
  EMA Lapsed: Docetaxel Mylan (docetaxel) — Mylan S.A.S.

  EMA status shows Docetaxel Mylan has lapsed; related indications include head and neck neoplasms, non-small cell lung carcinoma, adenocarcin…

• EMA withdrawal · 2012-06-14
  EMA Withdrawn: Docefrez (docetaxel) — Sun Pharmaceutical Industries Europe B.V.

  Withdrawn EMA entry for Docefrez (docetaxel) by Sun Pharmaceutical Industries Europe B.V.; listed indications include stomach neoplasms, ade…

• EMA withdrawal · 2010-03-26
  EMA Application withdrawn: Docetaxel Mylan (docetaxel) — Mylan S.A.S.

  Withdrawal of the EMA application for Docetaxel Mylan (docetaxel) by Mylan S.A.S., affecting multiple solid tumor indications including non-…

• EMA withdrawal · 2008-08-05
  EMA Application withdrawn: Orplatna (satraplatin) — Pharmion Ltd.

  The EMA withdrew the application for Orplatna (satraplatin) from Pharmion Ltd., with the therapeutic area listed as prostatic neoplasms.